Study of AZD2811 + durvalumab in ES-SCLC

Trial Identifier: D6132C00001
Sponsor: AstraZeneca
Start Date: February 2021
Primary Completion Date: June 2022
Study Completion Date: December 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish Translation
Polish Translation
Korean Translation

Trial Locations

Country Location
ES Sevilla, ES, 41071
ES Valencia, ES, 46015
KR Cheongju-si, KR, 28644
KR Jinju-si, KR, 52727
KR seoul, KR, 06351
KR Seoul, KR, 03722
KR Seoul, KR, 06591
KR Seoul, KR, 05505
PL Bydgoszcz, PL, 85-796
PL Olsztyn, PL, 10-357
PL Poznan, PL, 60-693
US, MI Grand Rapids, MI, US, 49503